{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:56:17Z","timestamp":1787849777714,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13256-018-1935-1","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T22:11:54Z","timestamp":1546899114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Doyne honeycomb retinal dystrophy \u2013 functional improvement following subthreshold nanopulse laser treatment: a case report"],"prefix":"10.1186","volume":"13","author":[{"given":"Andrea","family":"Cusumano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Falsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Cascella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"1935_CR1","doi-asserted-by":"publisher","first-page":"13067","DOI":"10.1073\/pnas.202491599","volume":"99","author":"LY Marmorstein","year":"2002","unstructured":"Marmorstein LY, et al. Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. Proc Natl Acad Sci. 2002;99:13067\u201372.","journal-title":"Proc Natl Acad Sci"},{"key":"1935_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/sj.eye.6701435","volume":"19","author":"N Narendran","year":"2005","unstructured":"Narendran N, Guymer RH, Cain M, Baird PN. Analysis of the EFEMP1 gene in individuals and families with early onset drusen. Eye. 2005;19:11\u20135.","journal-title":"Eye"},{"key":"1935_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/9722","volume":"22","author":"EM Stone","year":"1999","unstructured":"Stone EM, et al. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet. 1999;22:199\u2013202.","journal-title":"Nat Genet"},{"key":"1935_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/hmg\/5.7.1055","volume":"5","author":"CY Gregory","year":"1996","unstructured":"Gregory CY, et al. The gene responsible for autosomal dominant Doyne\u2019s honeycomb retinal dystrophy (DHRD) maps to chromosome 2p16. Hum Mol Genet. 1996;5:1055\u20139.","journal-title":"Hum Mol Genet"},{"key":"1935_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ajo.2005.09.001","volume":"141","author":"EH Souied","year":"2006","unstructured":"Souied EH, et al. Optical coherent tomography features of malattia leventinese. Am J Ophthalmol. 2006;141:404\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1935_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1055\/s-2005-857972","volume":"222","author":"MC Gaillard","year":"2005","unstructured":"Gaillard MC, et al. Optical coherence tomography in Malattia Leventinese. Klin Monatsbl Augenheilkd. 2005;222:180\u20135.","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1935_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00417-012-2106-5","volume":"251","author":"G Querques","year":"2013","unstructured":"Querques G, et al. Multimodal morphological and functional characterization of Malattia Leventinese. Graefes Arch Clin Exp Ophthalmol. 2013;251:705\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1935_CR8","doi-asserted-by":"publisher","first-page":"30469","DOI":"10.1074\/jbc.M403026200","volume":"279","author":"PA Klenotic","year":"2004","unstructured":"Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1): Implications for macular degenerations. J Biol Chem. 2004;279:30469\u201373.","journal-title":"J Biol Chem"},{"key":"1935_CR9","doi-asserted-by":"publisher","first-page":"11805","DOI":"10.1074\/jbc.M611029200","volume":"282","author":"N Kobayashi","year":"2007","unstructured":"Kobayashi N, et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem. 2007;282:11805\u201316.","journal-title":"J Biol Chem"},{"key":"1935_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0945-053X(99)00038-4","volume":"18","author":"R Giltay","year":"1999","unstructured":"Giltay R, Timpl R, Kostka G. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol. 1999;18:469\u201380.","journal-title":"Matrix Biol"},{"key":"1935_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-319-17121-0_21","volume":"854","author":"JD Hulleman","year":"2016","unstructured":"Hulleman JD. Malattia Leventinese\/Doyne Honeycomb Retinal Dystrophy: Similarities to Age-Related Macular Degeneration and Potential Therapies. Adv Exp Med Biol. 2016;854:153\u20138.","journal-title":"Adv Exp Med Biol"},{"key":"1935_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/IAE.0000000000000263","volume":"35","author":"EH Sohn","year":"2015","unstructured":"Sohn EH, et al. Comparison of drusen and modifying genes in autosomal dominant radial drusen and age-related macular degeneration. Retina. 2015;35:48\u201357.","journal-title":"Retina"},{"key":"1935_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ajo.2012.07.003","volume":"155","author":"E Lenassi","year":"2013","unstructured":"Lenassi E, et al. Laser clearance of drusen deposit in patients with autosomal dominant drusen (p.Arg345Trp in EFEMP1). Am J Ophthalmol. 2013;155:190\u20138.","journal-title":"Am J Ophthalmol"},{"key":"1935_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/lsm.21087","volume":"43","author":"JPM Wood","year":"2011","unstructured":"Wood JPM, Plunkett M, Previn V, Chidlow G, Casson RJ. Nanosecond pulse lasers for retinal applications. Lasers Surg Med. 2011;43:499\u2013510.","journal-title":"Lasers Surg Med"},{"key":"1935_CR15","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1167\/iovs.12-11203","volume":"54","author":"JPM Wood","year":"2013","unstructured":"Wood JPM, Shibeeb O, Plunkett M, Casson RJ, Chidlow G. Retinal damage profiles and neuronal effects of laser treatment: Comparison of a conventional photocoagulator and a novel 3-nanosecond pulse laser. Investig Ophthalmol Vis Sci. 2013;54:2305\u201318.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1935_CR16","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1167\/iovs.12-11204","volume":"54","author":"G Chidlow","year":"2013","unstructured":"Chidlow G, Shibeeb O, Plunkett M, Casson RJ, Wood JPM. Glial cell and inflammatory responses to retinal laser treatment: Comparison of a conventional photocoagulator and a novel, 3-nanosecond pulse laser. Investig Ophthalmol Vis Sci. 2013;54:2319\u201332.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1935_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/ceo.12247","volume":"42","author":"RH Guymer","year":"2014","unstructured":"Guymer RH, et al. Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function. Clin Exp Ophthalmol. 2014;42:466\u201379.","journal-title":"Clin Exp Ophthalmol"},{"key":"1935_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1096\/fj.14-262444","volume":"29","author":"AI Jobling","year":"2015","unstructured":"Jobling AI, et al. Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage. FASEB J. 2015;29:696\u2013710.","journal-title":"FASEB J"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1935-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-018-1935-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1935-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T19:10:14Z","timestamp":1578597014000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-018-1935-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1935"],"URL":"https:\/\/doi.org\/10.1186\/s13256-018-1935-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"22 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required. The patient gave written, informed consent. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. John Marshall is a consultant for Ellex. There are no other competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"5"}}